The Glooko team is thrilled to head to Las Vegas from April 22 to 24 for the 2026 American Association of Clinical Endocrinology (AACE) Annual Meeting, the premier event for endocrinology experts that brings together clinicians, researchers, and innovators to share cutting-edge science, clinical insights, and innovations shaping the future of endocrine care.
Our poster presentation, “Virtual Elimination of Severe Hypoglycemia Utilizing a Computerized Insulin Dosing Algorithm for Intravenous Insulin Infusions,” will take place at AACE on Thursday, April 23 from 11:10–11:25 a.m. PDT at Poster Station 4, Learning Zone, Caesars Forum. Paul Chidester, MD, FACP, Medical Director for EndoTool at Glooko and Joseph Aloi, MD, FACE, Section Chief, Endocrinology and Metabolism at Advocate Health Wake Forest Baptist Hospital, will share outcomes from Advocate Health’s use of the EndoTool Glucose Management System, developed by Monarch Medical Technologies, a Glooko Company, for inpatient glycemic care across its 19-hospital health system.
Poster Presentation
- Virtual Elimination of Severe Hypoglycemia Utilizing a Computerized Insulin Dosing Algorithm for Intravenous Insulin Infusions
- Authors: Joseph Aloi, MD, FACE, Advocate Health Wake Forest Baptist Hospital; Paul Chidester, MD, FACP, Glooko
- Conference: American Association of Clinical Endocrinology (AACE) 2026 Annual Meeting
About EndoTool
EndoTool is the leading FDA-cleared, patient-specific inpatient insulin-dosing software trusted by 8 of the top 10 U.S. health systems to support safer, more consistent glycemic management. The solution’s unique algorithm models each patient’s clinical characteristics and response to insulin to provide optimal dosing recommendations, and reduce the risk of severe hypoglycemia to virtually zero.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.